CSIMarket
 
Atossa Therapeutics Inc   (NASDAQ: ATOS)
Other Ticker:  
 
 
Price: $0.7686 $-0.01 -1.081%
Day's High: $0.7999 Week Perf: -4.52 %
Day's Low: $ 0.77 30 Day Perf: -16.89 %
Volume (M): 664 52 Wk High: $ 2.27
Volume (M$): $ 510 52 Wk Avg: $1.30
Open: $0.79 52 Wk Low: $0.72



 Market Capitalization (Millions $) 97
 Shares Outstanding (Millions) 126
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 0

Atossa Therapeutics Inc
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington that is primarily focused on developing innovative therapies that can prevent and treat breast cancer, as well as other medical conditions that are related to breast health. The companyes mission is to improve the lives of patients by creating new treatments that are safe, effective, and patient-friendly.

Atossa Therapeutics has a number of proprietary products and technologies that it is developing for breast cancer and other indications. One of the companyes flagship products is Endoxifen, which is a potent selective estrogen receptor modulator (SERM) that can be used to reduce the risk of developing breast cancer. Endoxifen has shown promising results in early-stage clinical trials, and the company is currently conducting more comprehensive clinical trials to evaluate its safety and efficacy.

In addition to Endoxifen, Atossa Therapeutics has also developed a range of other products that are designed to treat breast cancer and improve breast health. These products include:

- Topical Endoxifen: This is a topical form of Endoxifen that can be applied directly to the breast tissue. It is being developed for use in women who have been diagnosed with precancerous breast lesions or who are at high risk of developing breast cancer.
- Oral Endoxifen: This is an oral form of Endoxifen that can be taken by women who have been diagnosed with breast cancer or who are at high risk of developing the disease. It is currently in clinical trials to evaluate its safety and efficacy.
- Immunotherapies: Atossa Therapeutics is also developing a range of immunotherapies that can be used to treat breast cancer. These therapies are designed to stimulate the bodyes immune system to target and eliminate cancer cells.
- Breast Health Products: The company has also developed a range of products that are designed to improve breast health and reduce the risk of breast cancer. These products include a breast pump and a diagnostic device that can be used to detect breast cancer at an early stage.

Overall, Atossa Therapeutics is a leader in the development of innovative therapies for breast cancer and other breast health-related conditions. The companyes proprietary products and technologies show great promise in the fight against breast cancer, and its ongoing clinical trials are expected to provide important insights into the safety and efficacy of these products.


   Company Address: 107 Spring Street Seattle 98104 WA
   Company Phone Number: 588-0256   Stock Exchange / Ticker: NASDAQ ATOS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FGEN   -8.8%    
GTHX        0.28% 
HOWL        11.76% 
INBP   -20.51%    
XNCR   -5.97%    
ZLAB        0.58% 
• View Complete Report
   



Management Announcement

Atossa Therapeutics Advances Breast Cancer Treatment with Innovative Synergistic Therapies Amid Patent Developments

Published Thu, Jan 30 2025 1:17 PM UTC

In a dynamic and often challenging landscape for biopharmaceutical innovation, Atossa Therapeutics, Inc. (Nasdaq: ATOS) continues to establish itself as a vanguard in the fight against breast cancer. The Seattle-based company, dedicated to the prevention and treatment of this prevalent malignancy, recently navigated a significant hurdle in the realm of intellectual property ...

Clinical Study

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Tr...

Published Thu, Dec 12 2024 1:15 PM UTC

Unlocking New Frontiers in Breast Cancer Treatment: Synergistic Therapies and Clinical Advances by Atossa TherapeuticsIn a significant stride toward innovative cancer treatment, Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical firm, is making waves in the oncological community with its cutting-edge research and clinical trials aimed at improving outcomes for br...

Product Service News

Efficacy and Tolerability of 1 MG (Z)-Endoxifen Promising Insights from the Phase 2 KARISMA Study in Reducing Mammogr...

Published Wed, Dec 11 2024 1:15 PM UTC

Abstract Atossa Therapeutics has unveiled compelling data from its Phase 2 KARISMA-Endoxifen study, highlighting significant reductions in mammographic breast density among premenopausal women at risk of developing breast cancer. This article delves into the study findings that suggest 1 mg (Z)-Endoxifen may serve as a well-tolerated preventative therapy, offering new avenue...

Clinical Study

Atossa Therapeutics Advances (Z)-Endoxifen Research for Breast Cancer Treatment and Prevention

Published Mon, Nov 4 2024 11:30 AM UTC

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology, has recently reported significant developments related to its lead candidate, (Z)-Endoxifen. Two key announcements highlight the progress of (Z)-Endoxifen in clinical trials for breast cancer treatment and prevention, indicating a robust pipeline aim...

Management Announcement

Atossa Therapeutics: Navigating New FDA Regulations Amid Financial Challengesnn

Published Tue, Sep 10 2024 12:31 PM UTC


In a significant development for breast cancer awareness and early detection, the U.S. Food and Drug Administration (FDA) has implemented a final rule mandating patient notifications regarding breast density as part of updated mammography regulations. This move is hailed as a milestone in addressing a crucial risk factor for breast cancer, potentially leading to earlier...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com